Tenax Therapeutics Inc Total Liabilities
Tenax Therapeutics Inc total liabilities. Based on the latest financial reports, Tenax Therapeutics Inc (TENX) has total liabilities worth $8.07 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Tenax Therapeutics Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Tenax Therapeutics Inc (1995–2025)
Total liabilities of Tenax Therapeutics Inc from 1995 to 2025. This chart illustrates how Tenax Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore TENX long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Tenax Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Tenax Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Feelux Co. Ltd.
KO:033180
|
Korea | ₩563.86 Billion |
|
Wentel Engineering Holdings Berhad
KLSE:0298
|
Malaysia | RM16.88 Million |
|
Alkim Alkali Kimya AS
IS:ALKIM
|
Turkey | TL1.41 Billion |
|
GIIB Holdings Bhd
KLSE:7192
|
Malaysia | RM67.48 Million |
|
Mawana Sugars Limited
NSE:MAWANASUG
|
India | Rs5.98 Billion |
|
Korea Computer & Systems Inc
KQ:115500
|
Korea | ₩10.67 Billion |
|
Enzymatica publ AB
ST:ENZY
|
Sweden | Skr13.56 Million |
|
L.P.N. Development Public Company Limited
BK:LPN
|
Thailand | ฿12.24 Billion |
Liability Composition Analysis (1995–2025)
This chart breaks down Tenax Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see TENX asset base.
Liquidity & Leverage Metrics
Tenax Therapeutics Inc Total Liabilities Ratios Explained
Tenax Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 15.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tenax Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tenax Therapeutics Inc (1995–2025)
The table below shows the annual total liabilities of Tenax Therapeutics Inc from 1995 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $7.16 Million | +52.48% |
| 2024-12-31 | $4.69 Million | +30.85% |
| 2023-12-31 | $3.59 Million | +87.58% |
| 2022-12-31 | $1.91 Million | +9.41% |
| 2021-12-31 | $1.75 Million | -22.09% |
| 2020-12-31 | $2.24 Million | -13.49% |
| 2019-12-31 | $2.59 Million | +65.60% |
| 2018-12-31 | $1.57 Million | +55.19% |
| 2017-12-31 | $1.01 Million | -83.73% |
| 2016-12-31 | $6.20 Million | -50.66% |
| 2015-12-31 | $12.56 Million | +19.15% |
| 2014-12-31 | $10.54 Million | 0.00% |
| 2013-12-31 | $10.54 Million | +190.04% |
| 2012-12-31 | $3.64 Million | -46.24% |
| 2011-12-31 | $6.76 Million | +382.26% |
| 2010-12-31 | $1.40 Million | +16.95% |
| 2009-12-31 | $1.20 Million | -33.10% |
| 2008-12-31 | $1.79 Million | -27.15% |
| 2007-12-31 | $2.46 Million | +479.35% |
| 2006-12-31 | $424.57K | +35.24% |
| 2005-12-31 | $313.94K | -13.16% |
| 2004-12-31 | $361.51K | +8.32% |
| 2003-12-31 | $333.75K | +309.28% |
| 2002-12-31 | $81.55K | -79.52% |
| 2001-12-31 | $398.09K | +15.24% |
| 2000-12-31 | $345.44K | -42.43% |
| 1999-12-31 | $600.00K | -5.42% |
| 1998-12-31 | $634.36K | +5.61% |
| 1997-12-31 | $600.67K | -39.42% |
| 1996-12-31 | $991.54K | 0.00% |
| 1995-12-31 | $991.54K | -- |
About Tenax Therapeutics Inc
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imat… Read more